Literature DB >> 21190901

Rhythmic delta activity represents a form of nonconvulsive status epilepticus in anti-NMDA receptor antibody encephalitis.

McNeill P Kirkpatrick1, Charles D Clarke, Hasan H Sonmezturk, Bassel Abou-Khalil.   

Abstract

Anti-NMDA receptor antibody encephalitis is a limbic encephalitis with psychiatric manifestations, abnormal movements, coma, and seizures. The coma and abnormal movements are not typically attributed to seizure activity, and slow activity is the most common EEG finding. We report drug-resistant nonconvulsive status epilepticus as the basis for coma in a 19-year-old woman with anti-NMDA receptor antibodies and a mediastinal teratoma. The EEG showed generalized rhythmic delta activity, with evolution in morphology, frequency, and field typical of nonconvulsive status epilepticus. The status was refractory to antiepileptic drugs, repeated drug-induced coma, resection of the tumor, intravenous steroids, rituximab, and plasmapheresis. She awoke after the addition of felbamate, and the rhythmic delta activity ceased. The rhythmic delta activity described with coma in anti-NMDA receptor antibody encephalitis may represent a pattern of status epilepticus in some patients. Felbamate, which has NMDA receptor antagonist activity, should be studied as a therapeutic agent in this condition.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190901     DOI: 10.1016/j.yebeh.2010.11.020

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  19 in total

1.  Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.

Authors:  Qi Huang; Yuan Wu; Rongfa Qin; Xing Wei; Meigang Ma
Journal:  J Neurol       Date:  2016-09-15       Impact factor: 4.849

Review 2.  Movement disorders in paraneoplastic and autoimmune disease.

Authors:  Jessica Panzer; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

3.  Current approaches to the treatment of paraneoplastic encephalitis.

Authors:  Wolfgang Grisold; Bruno Giometto; Roberta Vitaliani; Stefan Oberndorfer
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

4.  Anti-NMDA receptor encephalitis presenting with focal non-convulsive status epilepticus in a child.

Authors:  E M Goldberg; K S Taub; S K Kessler; N S Abend
Journal:  Neuropediatrics       Date:  2011-11-22       Impact factor: 1.947

5.  Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings.

Authors:  Leyla Baysal-Kirac; Erdem Tuzun; Ece Erdag; Canan Ulusoy; Ebru Nur Vanli-Yavuz; Esme Ekizoglu; Sian Peach; Mine Sezgin; Nerses Bebek; Candan Gurses; Aysen Gokyigit; Angela Vincent; Betul Baykan
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

6.  Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis.

Authors:  Sarah E Schmitt; Kimberly Pargeon; Eric S Frechette; Lawrence J Hirsch; Josep Dalmau; Daniel Friedman
Journal:  Neurology       Date:  2012-08-29       Impact factor: 9.910

Review 7.  [Update on anti-N-methyl-D-aspartate receptor encephalitis].

Authors:  S Kovac; J Alferink; D Ahmetspahic; V Arolt; N Melzer
Journal:  Nervenarzt       Date:  2018-01       Impact factor: 1.214

8.  Clinical analysis on anti-N-methyl-D-aspartate receptor encephalitis cases: Chinese experience.

Authors:  Xiaoqin Huang; Chunqiu Fan; Jian Wu; Jing Ye; Shuqin Zhan; Haiqing Song; Aihua Liu; Yingying Su; Jianping Jia
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 9.  [Research progress on electroencephalogram characteristics of anti-N-methyl-D-aspartate receptor encephalitis].

Authors:  Xiaoxiao Liu; Liqiong Guo; Cheng Liang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

10.  Modulation of Immunity and the Inflammatory Response: A New Target for Treating Drug-resistant Epilepsy.

Authors:  Nian Yu; Hao Liu; Qing Di
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.